Abstract:Abstract Globally, lifespan continues to increase. A growing challenge is how to maintain a healthy aging population. In hematopoiesis, healthspan is limited by a decline in regenerative capacity and overproduction of myeloid cell types at the expense of lymphoid cell types. These alterations contribute to decreased immune function, poor response to vaccination and increased susceptibility to myeloid neoplasms. Methods to extend hematopoietic healthspan are unclear, in part due to our relatively poor understanding of the factors controlling aging. To address this gap in knowledge, we utilized mouse models to examine at what age did impaired regenerative capacity and myeloid-biased hematopoiesis begin to occur. We find that these phenotypes become significant by 9-12 months of age, representing middle age in mice. Through reciprocal transplantation studies of purified long-term hematopoietic stem cells (LT-HSCs) between young and middle-aged mice, we find that the middle-aged bone marrow (BM) microenvironment is sufficient to cause impaired regenerative capacity and myeloid-biased hematopoiesis from young LT-HSCs. These studies clearly implicate components of the BM microenvironment at middle age as causing hematopoietic aging. To uncover the factors altered in the middle-aged BM microenvironment that cause hematopoietic stem and progenitor cell aging, we utilized single cell RNA-Seq and ELISA analysis. Together, these identified a reduction in Insulin-Like Growth Factor-1 (IGF1) in the BM microenvironment as the top candidate regulator of hematopoietic stem and progenitor cell aging. Expression of the receptor for IGF1, IGF1R, was dynamically altered on hematopoietic stem and progenitor cell populations with aging, suggesting that these respond to altered local levels of IGF1. In vitro colony-forming unit studies demonstrate that stimulating hematopoietic stem and progenitor cells isolated from middle-aged mice with exogenous IGF-1 ligand resulted in a dose-dependent suppression of myeloid cell overproduction, rescuing the aging phenotype. Finally, direct restoration of IGF1 levels in the BM microenvironment by short-term intrafemoral injection, at middle age, suppressed myeloid cell overproduction and restored B cell production in the BM and peripheral blood. In summary, this study reveals a novel role for IGF1 in hematopoietic aging. We show that decline in local levels of IGF1 in the BM microenvironment at middle age cause hematopoietic aging. In addition, we demonstrate that short-term restoration of IGF1 at middle age can rescue hematopoietic aging. IGF1 thus represents an attractive candidate molecule to restore hematopoietic regenerative capacity and balanced lineage cell production to extend hematopoietic healthspan into older age. Disclosures No relevant conflicts of interest to declare.

Overexpression of Insulin-Like Growth Factor 1 Enhanced the Osteogenic Capability of Aging Bone Marrow Mesenchymal Stem Cells

Age-Related Insulin-Like Growth Factor Binding Protein-4 Overexpression Inhibits Osteogenic Differentiation Of Rat Mesenchymal Stem Cells

The Middle-Aged Bone Marrow Microenvironment Drives Hematopoietic Stem Cell Aging through Altered Production of Insulin-like Growth Factor-1 (IGF1)

Age-related Changes in Bone Marrow Mesenchymal Stromal Cells

Effects of insulin growth factor I and bone morphogenetic protein-2 combined application on promoting proliferation and differentiation of MC 3T3-E1 and NIH 3T3 cells

[Effects of IGF-I and BMP-2 Combined Application on Promoting Proliferation, Differentiation and Calcification of MC 3T3-E1 and NIH 3T3 Cells].

Constitutively activated AMPKα1 protects against skeletal aging in mice by promoting bone‐derived IGF‐1 secretion

γ-Secretase inhibitor reverts the Notch signaling attenuation of osteogenic differentiation in aged bone marrow mesenchymal stem cells

Bone marrow-derived IGF-1 orchestrates maintenance and regeneration of the adult skeleton

Insulin-like Growth Factor 2 (IGF2) Potentiates BMP9-induced Osteogenic Differentiation and Bone Formation

IGF-1 Induces Osteogenic Differentiation of Rat Bone Marrow Mesenchymal Stem Cells by Promoting SOX4 via the MAPK/ERK Pathway

Bone marrow mesenchymal stem cells overexpressing stromal cell- derived factor 1 aid in bone formation in osteoporotic mice

Cardiac-specific Overexpression of Insulin-Like Growth Factor 1 Attenuates Aging-Associated Cardiac Diastolic Contractile Dysfunction and Protein Damage.

Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline

Inflammatory Microenvironment Accelerates Bone Marrow Mesenchymal Stem Cell Aging

Bmi1 Overexpression in Mesenchymal Stem Cells Exerts Antiaging and Antiosteoporosis Effects by Inactivating p16/p19 Signaling and Inhibiting Oxidative Stress

Effect of Insulin on Bone Formation Ability of Rat Alveolar Bone Marrow Mesenchymal Stem Cells

Overexpression of Bone Morphogenetic Protein-1 Promotes Osteogenesis of Bone Marrow Mesenchymal Stem Cells in Vitro

Mesoporous Bioactive Glass Scaffolds for the Delivery of Bone Marrow Stem Cell-Derived Osteoinductive Extracellular Vesicles Lncrna Promote Senescent Bone Defect Repair by Targeting the Mir-1843A-5p/mob3a/yap Axis.

IGF-1 enhances BMSC viability, migration, and anti-apoptosis in myocardial infarction via secreted frizzled-related protein 2 pathway

Impact of Donor Age on the Osteogenic Supportive Capacity of Mesenchymal Stromal Cell-Derived Extracellular Matrix